Thank you for your interest in Adaptimmune. We are a leader in the TCR T-cell therapy space focused on novel cancer immunotherapy products. We utilize the body’s own machinery – the T-cell – to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). The result of our efforts are SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell therapies that can recognize cancer proteins, and as a result detect and fight cancer within patients.
SPEAR T-cell therapies targeting MAGE-A10, MAGE-A4, AFP, and NY-ESO are moving through clinical studies in multiple cancer types.
|$11.710.00 (0.00%)Data provided by Nasdaq. Minimum 15 minutes delayed.|
|09/07/18||Adaptimmune Therapeutics plc Announces Closing of Registered Direct Offering of American Depositary Shares|
|PHILADELPHIA, Pa. and OXFORD, U.K., Sept. 07, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced the closing of its previously announced registered direct offering of its American Depositary Shares (“ADSs”). Adaptimmune sold 10,000,000 ADSs at a price of $10.00 per ADS.
Net proceeds of the offering are approximately $100.0 million. Adaptimmune intends to use the net proceeds from this offering to ... |
|09/05/18||Adaptimmune Therapeutics plc Announces Registered Direct Offering of American Depositary Shares|
|PHILADELPHIA and OXFORD, United Kingdom, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that it has entered into a definitive agreement with Matrix Capital Management Company, LP (“Matrix”), New Enterprise Associates 16, L.P., New Enterprise Associates 14, L.P. (“NEA”) and Syncona Portfolio Limited (“Syncona”), to purchase an aggregate of US$100 million of its American Depositary Shares... |
|08/15/18||Third Dosing Cohort to be initiated in MAGE-A4 SPEAR T-cell Basket Study After Favorable Review of Safety from One Billion Cell Dose Cohort|
|PHILADELPHIA and OXFORD, United Kingdom, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced a favorable review of safety data from the second dose cohort of patients who received one billion transduced SPEAR T‑cells targeting MAGE-A4 in the ongoing basket study in nine solid tumor indications. Based on these data, the Safety Review Committee (SRC) has endorsed dose escalation to the third dose cohort of 1.2 ... |
|08/02/18||Adaptimmune Reports Second Quarter 2018 Financial Results and Business Update|
|- Dosing patients in both MAGE-A10 pilot studies in third cohort with range of one to six billion cells -
- NY-ESO program transitioned to GSK allows clinical focus on wholly owned assets -
- Guidance confirmed, funded through to early 2020 -
- Conference call to be held today at 8:00 a.m. EDT (1:00 p.m. BST) -
PHILADELPHIA and OXFORD, United Kingdom, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported f... |
|There are currently no events scheduled.|
Receive E-mail Alerts|
|Sign up to receive e-mail alerts whenever Adaptimmune posts new information to the site. Just enter your e-mail address and click Submit.|